Skip to Main Content

Last week, the genome-editing scientists behind base editing, a technology dubbed CRISPR 2.0, gathered for an update from the competition. Intellia Therapeutics, a company invested in the classic form of CRISPR, was to unveil its take on base editing, a refined approach to fixing DNA that corrects single letters of the genome without breaking the double helix.

The presentation, hosted by the famed Cold Spring Harbor Laboratory, sounded familiar.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!